Outlook Therapeutics, Inc.
OTLK
Rank in Stocks
#22216
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced... Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Share Price
$0.39
Last synced: 2026-11-20
Market Cap
$53.33M
Change (1 day)
-2.74%
Change (1 year)
-79.26%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Outlook Therapeutics, Inc. (OTLK)
Category
Healthcare
EPS for Outlook Therapeutics, Inc. (OTLK)
EPS as of June 2026 TTM: $-1.10
According to Outlook Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.10. At the end of 2025 the company had an EPS of $-1.79, an increase over its 2024 EPS of $-4.06.
EPS history for Outlook Therapeutics, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.10 | -38.55% |
| 2025 | $-1.79 | -55.91% |
| 2024 | $-4.06 | -15.42% |
| 2023 | $-4.80 | -22.95% |
| 2022 | $-6.23 | -11.00% |
| 2021 | $-7.00 | -48.03% |
| 2020 | $-13.47 | -65.98% |
| 2019 | $-39.60 | -79.67% |
| 2018 | $-194.80 | -27.10% |
| 2017 | $-267.20 | -54.50% |
| 2016 | $-587.20 | 4.09% |
| 2015 | $-564.14 | 53,627.62% |
| 2014 | $-1.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,523.64% |
US
|
|
| $-7.07 | 542.73% |
US
|
|
| $-5.29 | 380.91% |
AU
|
|
| $12.73 | -1,257.47% |
BE
|
|
| $21.56 | -2,060.00% |
NL
|
Questions about Outlook Therapeutics, Inc.'s earnings per share (EPS)
What is Outlook Therapeutics, Inc.'s earnings per share (EPS)?
Outlook Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.10, as of Jun 2026.
What was Outlook Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Outlook Therapeutics, Inc.'s earnings per share (EPS) was $-1.79, compared with $-4.06 in 2024.
How has Outlook Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Outlook Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.79) and lowest in 2020 ($-13.47).
How does Outlook Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Outlook Therapeutics, Inc.'s earnings per share (EPS) ($-1.10) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.